References
- Øst A., Lindstrøm P., Christensson B., Gyllenhammar H., Engstedt L. Acute leukemia in a defined geographic area. Incidence, clinical history and prognosis. Scand. J. Haematol. 1984; 33: 160–170
- Brincker H., Christensen B. E. Long-term survival and late relapses in acute leukaemia in adults. Br. J. Haematol. 1990; 74: 156–160
- Wahlin A., Hornsten P., Jonsson H. Remission rate and survival in acute myeloid leukemia: Impact of selection and chemotherapy. Eur. J. Haematol. 1991; 46: 240–247
- Bennett J. M., Catovsky D., Daniel M. T., Flandrin G., Galton D. A. G., Gralnick H. R., Sultan C. Proposals for the classification of the acute leukaemias. Br. J. Haematol. 1976; 33: 451–458
- Marcus R. E., Catovsky D., Johnson S. A., Gregory W. M., Talavera J. G., Goldman J. M., Galton S. A. G. Adult acute lymphoblastic leukaemia: A study of prognostic features and response to treatment over a ten year period. Br. J. Cancer 1986; S3: 175–180
- Brincker H. Population-based age- and sex-specific incidence rates in the 4 main types of leukemia. Scand. J. Haematol. 1982; 29: 241–249
- The Toronto Leukemia Study Group. Results of chemotherapy for unselected patients with acute myeloblastic leukemia: effect of exclusions on interpretation of results. Lancet 1986; 1: 786–788
- Mertelsmann R., Thaler H. T., To L., Gee T. A., McKenzie S., Schauer P., Friedman A., Arlin Z., Cirrin-cione C., Clarkson B. Morphological classification, response to therapy, and survival in 263 adult patients with acute non-lymphoblastic leukemia. Blood 1980; 56: 773–781
- Rees J. K. H., Gray R. G., Swirsky D., Hayhoe F. G. J. Principal results of the Medical Research Council's 8th acute myeloid leukemia trial. Lancet 1986; 2: 1236–1241
- Bandini G., Zuffa E., Rosti G., Battista R., Emilio E. D., Leoni F., Ciolli S., Barbul T., Bassan R., Todeschini G., Perona G., Scapoli G. L., Mangoni L., Morra E., Di Priso U., Visani G., Tura S. Long-term outcome of adults with acute myelogenous leukaemia: results of a prospective, randomized study of chemotherapy with a minimal follow-up of 7 years. Br. J. Haematol. 1991; 11: 486–490
- Phillips G. L., Reece D. E., Shepherd J. D., Barnett M. J., Brown R. A., Frei-Lahr D. A., Klingermann H. G., Bolwill B. J., Spinelli J. J., Herzig R. H., Herzig G. P. High-dose cytarabine and daunorubicin induction and post-remission chemotherapy for the treatment of acute myelogenous leukemia in adults. Blood 1991; 11: 1429–1435
- Evensen S. A., Brinch L., Stavem P., Tjønnfjord G. Survival in 91 adults with acute myelogenous leukaemia treated with 1–6 intensive courses of chemotherapy. J. Intern. Med. 1992; 132: 433–437